Abstract
Bryostatin 1 represents a novel and potent therapeutic lead with a unique activity profile. Its natural and synthetic availability is severely limited. Function oriented synthesis provides a means to address this supply problem through the design of synthetically more accessible simplified structures that at the same time incorporate improved functional activity. Pharmacophore searching and a new computer aided visualization of a possible binding mode are combined with an understanding of function and knowledge of synthesis to design and prepare a new and simplified compound with bryostatin-like function in biological systems. This new compound is a potent ligand for protein kinase C in vitro (Ki = 8.0 nM). More significantly, the described molecule retains the functional ability to translocate a PKCδ-GFP fusion protein in RBL cells. The extent of protein translocation and the sub-cellular localization induced by this new compound is similar to that seen in response to bryostatin 1, indicating that the new molecule retains the functional activity of the natural product but is simpler and can be synthesized in a practical fashion.
Keywords: Bryostatin, Pharmacophore, RBL cells
Current Drug Discovery Technologies
Title: Function Oriented Synthesis: The Design, Synthesis, PKC Binding and Translocation Activity of a New Bryostatin Analog
Volume: 1 Issue: 1
Author(s): Paul A. Wender, Jeremy L. Baryza, Stacey E. Brenner, Michael O. Clarke, Madeleine L. Craske, Joshua C. Horan and Tobias Meyer
Affiliation:
Keywords: Bryostatin, Pharmacophore, RBL cells
Abstract: Bryostatin 1 represents a novel and potent therapeutic lead with a unique activity profile. Its natural and synthetic availability is severely limited. Function oriented synthesis provides a means to address this supply problem through the design of synthetically more accessible simplified structures that at the same time incorporate improved functional activity. Pharmacophore searching and a new computer aided visualization of a possible binding mode are combined with an understanding of function and knowledge of synthesis to design and prepare a new and simplified compound with bryostatin-like function in biological systems. This new compound is a potent ligand for protein kinase C in vitro (Ki = 8.0 nM). More significantly, the described molecule retains the functional ability to translocate a PKCδ-GFP fusion protein in RBL cells. The extent of protein translocation and the sub-cellular localization induced by this new compound is similar to that seen in response to bryostatin 1, indicating that the new molecule retains the functional activity of the natural product but is simpler and can be synthesized in a practical fashion.
Export Options
About this article
Cite this article as:
Wender A. Paul, Baryza L. Jeremy, Brenner E. Stacey, Clarke O. Michael, Craske L. Madeleine, Horan C. Joshua and Meyer Tobias, Function Oriented Synthesis: The Design, Synthesis, PKC Binding and Translocation Activity of a New Bryostatin Analog, Current Drug Discovery Technologies 2004; 1 (1) . https://dx.doi.org/10.2174/1570163043484888
DOI https://dx.doi.org/10.2174/1570163043484888 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Green Approach Towards Size Controlled Synthesis of Biocompatible Antibacterial Metal Nanoparticles in Aqueous Phase Using Lysozyme
Current Nanoscience Design and Development of Molecular Imaging Probes
Current Topics in Medicinal Chemistry The Past, Present and Future Subclassification of Patients with Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology In-silico Designing, ADMET Analysis, Synthesis and Biological Evaluation of Novel Derivatives of Diosmin Against Urease Protein and Helicobacter pylori Bacterium
Current Topics in Medicinal Chemistry Design and Synthesis of Curcumin-Like Diarylpentanoid Analogues as Potential Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Studies on the Biotransformations and Biodistributions of Metal-Containing Drugs Using X-Ray Absorption Spectroscopy
Current Topics in Medicinal Chemistry Prediction of Protein Quaternary Structure with Feature Selection and Analysis Based on Protein Biological Features
Protein & Peptide Letters Evaluation of the Soluble Pectin Content in Culinary Preparations
Current Nutrition & Food Science Cytarabine and Ferric Carboxymaltose (Fe+3) Increase Oxidative Damage and Alter Serotonergic Metabolism in Brain
CNS & Neurological Disorders - Drug Targets Uridine Function in the Central Nervous System
Current Topics in Medicinal Chemistry Disorder in Milk Proteins: Caseins, Intrinsically Disordered Colloids
Current Protein & Peptide Science Development and Validation of a Simple LC-UV Method to Assay Doxazosin in Polymeric Nanocapsules and Tablets
Current Pharmaceutical Analysis Elucidation of S-Allylcysteine Role in Inducing Apoptosis by Inhibiting PD-L1 Expression in Human Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Theranostic Nanomedicine; A Next Generation Platform for Cancer Diagnosis and Therapy
Mini-Reviews in Medicinal Chemistry Multi-Target Drugs for Neglected Diseases
Current Pharmaceutical Design Oxidative Stress and Antioxidant Potential of One Hundred Medicinal Plants
Current Topics in Medicinal Chemistry Novel Biomarkers Assessing the Calcium Deposition in Coronary Artery Disease
Current Medicinal Chemistry Deciphering Role of Cytokines for Therapeutic Strategies Against Rheumatoid Arthritis
Current Drug Targets Development and Characterization of Doxorubicin Bearing Vitamin B12 Coupled Sterically Stabilized Liposomes for Tumor Targeting
Current Nanoscience Structure-Based Rationale for Interleukin 5 Receptor Antagonism
Current Pharmaceutical Design